Антихолинергические препараты длительного действия в лечении бронхиальной астмы


Е.А. Ушкалова

Кафедра общей и клинической фармакологии РУДН, Москва
В статье представлен обзор исследований, посвященных изучению роли тиотропия бромида в лечении бронхиальной астмы (БА), раскрыты предпосылки для применения антихолинергических препаратов длительного действия при БА и фармакологические свойства тиотропия бромида. В настоящее время доказано, что добавление тиотропия к стандартной терапии больных тяжелой, плохо контролируемой БА приводит к улучшению функции легких и снижению риска обострений. Продолжающиеся исследования препарата могут расширить круг его показаний при БА.

Литература


  1. Braman S.S., The Global Burden of Asthma. Chest 2006;130;4S–12S.
  2. Bateman E.D., Hurd S.S., Barnes P.J., Bousquet J., Drazen J.M., FitzGerald M., Gibson P., Ohta K., O’Byrne P., Pedersen S.E., Pizzichini E., Sullivan S.D., Wenzel S.E., Zar H.J.Global strategy for asthma management and prevention: GINA executive summary. Eur. Respir. J. 2008;31(1):143–78.
  3. Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma–summary report 2007, J. Allergy Clin. Immunol. 2007;120(5 Suppl):S94–138.
  4. Garner R., Kohen D. Changes in the prevalence of asthma among Canadian children, Health Rep. 2008;19(2):45–50.
  5. Социально-экономическое бремя брон-хиальной астмы и хронической обструктивной болезни легких в Российской Федерации, РРОФ «Качество жизни» НИИ КЭФФ. М., 2009. http://www,mednet,ru/ru/novosti/1008-26052011--bolee-300-mln-paczientov-v-mire-i-900-tysyach-v-rossii--oficzialnaya-statistika-zabolevaemosti-bronxialnoj-astmoj,html
  6. Schluger N.W., Koppaka R. Lung disease in a global context, A call for public health action, Ann. Am. Thorac. Soc. 2014;11(3):407–16.
  7. Pawankar R., Canonica G.W., Holgate S.T., Lockey R.F. Allergic diseases and asthma: a major global health concern. Curr. Opin. Allergy Clin. Immunol. 2012;12:39–41.
  8. Anandan C., Nurmatov U., van Schayck O.C., Sheikh A. Is the prevalence of asthma declining? Systematic review of epidemiological studies, Allergy. 2010;65:152–67.
  9. Diaz-Guzman E., Mannino D.M. Airway obstructive diseases in older adults: from detection to treatment. J. Allergy Clin. Immunol. 2010;126:702–9.
  10. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128.
  11. Silva G.E., Sherrill D.L., Guerra S., Barbee R.A. Asthma as a risk factor for COPD in a longitudinal study. Chest. 2004;126:59–65.
  12. Soriano J.B., Davis K.J., Coleman B., Visick G., Mannino D., Pride N.B.The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest. 2003;124:474–78.
  13. Sims E.J., Price D., Haughney J., Ryan D., Thomas M. Current control and future risk in asthma management. Allergy Asthma Immunol. Res. 2011;3:217–25.
  14. von Bülow A., Backer V., Porsbjerg C. Severe asthma – where are we today?. Ugeskr Laeger. 2014;176(3A).
  15. Bateman E.D., Reddel H.K., Eriksson G., Peterson S., Ostlund O., Sears M.R., Jenkins C., Humbert M., Buhl R., Harrison T.W., Quirce S., O’Byrne P.M. Overall asthma control: the relationship between current control and future risk. J. Allergy Clin. Immunol. 2010;125(3):600–08.
  16. Price D., Fromer L., Kaplan A., van der Molen T., Roman-Rodriguez M. Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? NPJ. Prim. Care Respir. Med. 2014;24:14023.
  17. Restrepo R.D. Use of inhaled anticholinergic agents in obstructive airway disease. Respir. Care 2007;52:833–51.
  18. Yohannes A.M., Connolly M.J., Hanania N.A. Ten years of tiotropium: clinical impact and patient perspectives. Int. J. Chron. Obstruct Pulmon. Dis. 2013;8:117–25.
  19. Brown S.M., Koarai A., Sturton R.G., Nicholson A.G., Barnes P.J., Donnelly L.E. A role for M(2) and M(3) muscarinic receptors in the contraction of rat and human small airways. Eur. J. Pharmacol. 2013;702:109–15.
  20. Olin J.L., Tiotropium: An Inhaled Anticholinergic for Chronic Obstructive Pulmonary Disease, Am. J. Health Syst. Pharm. 2005;62(12):1263–69.
  21. Wollin L., Pieper M. Tiotropiumbromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD. Pulm. Pharmacol. Ther. 2010;23:345–54.
  22. Bos I., Gosens R., Zuidhof A., Schaafsma D, Halayko A.J., Meurs H., Zaagsma J. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison, Eur. Respir. J. 2007;30:653–61.
  23. Buels K., Jacoby D., Fryer A. Nonbronchodilating mechanisms of tiotropium prevent airway hyperreactivity in a guinea pig model of allergic asthma. Br. J. Pharmacol. 2012;65:1501–14.
  24. Gosens R. Inhibition of allergen-induced airway remodeling by tiotropium and budesonide: a comparative study, Abstract A269 presented at the 103rd Annual International Conference of the American Thoracic Society: San Francisco, CA, USA, 2007.
  25. Gosens R., Bos I.S.T., Zaagsma J., Meurs H. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling, Am. J. Respir. Crit. Care Med 2005;171:1096–102.
  26. Bourbeau J., Bartlett S.J. Patient adherence in COPD. Thorax. 2008;63:831–38.
  27. Rodrigo G.J., Castro-Rodriguez J.A. What is the role of tiotropium in asthma? A systematic review with meta-analysis. Chest. 2014 Oct 16
  28. Befekadu E., Onofrei C., Colice G.L. Tiotropium in asthma: a systematic review. J. Asthma Allergy. 2014;7:11–21.
  29. Novelli F., Costa F., Latorre M., Malagrino L., Celi A., Vagaggini B., Paggiaro P. Tiotropium: a new therapeutic option in asthma. Monaldi Arch Chest Dis. 2013;79(3–4):109–15.
  30. Vogelberg C., Engel M., Moroni-Zentgraf P., Leonaviciute-Klimantaviciene M., Sigmund R., Downie J., Nething K., Vevere V., Vandewalker M. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study. Respir. Med. 2014;108(9):1268–76.
  31. Kerstjens H.A.M., Engel M., Dahl R., Paggiaro P., Beck E., Vandewalker M., Sigmund R., Seibold W., Moroni-Zentgraf P., Bateman E.D. Tiotropium in asthma poorly controlled with standard combination therapy. N. Engl. J. Med 2012;367:1198–207.
  32. O’Connor B.J., Towse L.J., Barnes P.J. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am. J. Respir. Crit. Care Med. 1996;154(4 Pt 1):876–80.
  33. Asthma: new indication for Spiriva® (tiotropium) Respimat®* in the EU may offer millions of adults a significant advance in asthma care http://www,boehringer-ingelheim,com/news/news_releases/press_releases/2014/08_september_2014_asthma,html
  34. FitzGerald J.M., Kerstjens H.A.M., Paggiaro P., et al. Once-daily tiotropium Respimat add-on to ICS±LABA improves control across asthma severities. ERS abstract No 189437.
  35. Bollmeier S.G., Lee S.Y. The emerging role of tiotropium for patients with asthma. Ann. Pharmacother. 2013;47(5):704–13.
  36. Alagha K., Palot A., Sofalvi T., Pahus L., Gouitaa M., Tummino C., Martinez S., Charpin D., Bourdin A., Chanez P. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Ther. Adv. Chronic Dis. 2014;5(2):85–98.
  37. Fardon T., Haggart K., Lee D., Lipworth B. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir. Med. 2007;101:1218–28.
  38. Magnussen H., Bugnas B., van Noord J., Schmidt P., Gerken F., Kesten S. Improvements with tiotropium in COPD patients with concomitant asthma. Respir. Med. 2008;102(1):50–6.
  39. Park H., Yang, M., Park C., Kim T.B., Moon H.B., Min K.U., Kim Y.Y., Cho S.H. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy. 2009;64:778–83.
  40. Peters S.P., Kunselman S.J., Icitovic N., Moore W.C., Pascual R., Ameredes B.T., Boushey H.A., Calhoun W.J., Castro M., Cherniack R.M., Craig T., Denlinger L., Engle L.L., DiMango E.A., Fahy J.V., Israel E., Jarjour N., Kazani S.D., Kraft M., Lazarus S.C., Lemanske R.F. Jr, Lugogo N., Martin R.J., Meyers D.A., Ramsdell J., Sorkness C.A., Sutherland E.R., Szefler S.J., Wasserman S.I., Walter M.J., Wechsler M.E., Chinchilli V.M., Bleecker E.R.; National Heart, Lung, and Blood Institute Asthma Clinical Research Network.Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N. Engl. J. Med. 2010;363:1715–26.
  41. Kerstjens H.A.M., Disse B., Schröder-Babo W., Bantje T.A., Gahlemann M., Sigmund R., Engel M., van Noord J.A. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial, J. Allergy Clin. Immunol. 2011;128:308–14.
  42. Bateman E., Kornmann O., Schmidt P., Pivova-rova A., Engel M., Fabbri L.M. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients withasthma. J. Allergy Clin. Immunol. 2011;128:315–22.
  43. van Noord J.A., Cornelissen P.J., Aumann J.L., Platz J., Mueller A., Fogarty C. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir. Med. 2009;103(1):22–9.
  44. Rashid Q., Klein R. Tiotropium in the treatment of patients with asthma. South Med. J. 2014;107(5):330–37.
  45. Tian J.W., Chen J.W., Chen R., Chen X. Tiotropium versus placebo for inadequately controlled asthma: a meta-analysis. Respir. Care. 2014;59(5):654–66.
  46. Adams K.S., Lowe D.K. Tiotropium for adults with inadequately controlled persistent asthma. Ann. Pharmacother. 2013;47(1):117–23.
  47. Price D.B., Kaplan A., Jones R., et al. Real-life prescribing and outcomes of long-acting anticholinergic therapy in adult asthma patients in UK clinical practice. Am. J. Respir. Crit. Care Med. 2013;187:abs A2729.
  48. Abadoglu O., Berk S. Tiotropium may improve asthma symptoms and lung function in asthmatic patients with irreversible airway obstruction: The real life data. Clin. Respir. J. 2014.
  49. Willson J., Bateman E.D., Pavord I., Lloyd A., Krivasi T., Esser D. Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists, Appl Health Econ Health Policy. 2014;12(4):447–59.
  50. Mattishent K., Thavarajah M., Blanco P., Gilbert D., Wilson A.M., Loke Y.K. Meta-review: adverse effects of inhaled corticosteroids relevant to older patients, Drugs. 2014;74(5):539–47.
  51. Casarosa P., Pieper M.P., Gantner F. Cross-talk between the human muscarinic M3 and 2 receptors: evidence for heterologous desensitization, Am. J. Respir. Crit. Care Med. 2010;181:abs A6373.
  52. Soler X., Ramsdell J. Anticholinergics/Antimuscarinic Drugs in Asthma. Curr. Allergy Asthma Rep. 2014;14(12):484.
  53. Ahmad Z., Singh S.K. Relative and additional bronchodilator response of salbutamol and ipratropium in smoker and nonsmoker asthmatics. J. Asthma. 2010;47(3):340–43.
  54. Kanazawa H. Anticholinergic agents in asthma: chronic bronchodilator therapy, relief of acute severe asthma, reduction of chronic viral inflammation and prevention of airway remodeling. Curr. Opin. Pulm. Med. 2006;12(1):60–7.
  55. Profita M., Bonanno A., Siena L., Bruno A., Ferraro M., Montalbano A.M., Albano G.D., Riccobono L., Casarosa P., Pieper M.P., Gjomarkaj M. Smoke, choline acetyltransferase, muscarinic receptors, and fibroblast proliferation in chronic obstructive pulmonary disease. J. Pharmacol. Exp. Ther. 2009;329(2):753–63.
  56. Morcillo E.J., Cortijo J. Mucus and MUC in asthma, Curr Opin Pulm Med, 2006;12(1):1–6,
  57. Cortijo J., Mata M., Milara J., Donet E., Gavalda A., Miralpeix M., Morcillo E.J. Aclidinium inhibits cholinergic and tobacco smoke-induced MUC5AC in human airways. Eur. Respir. J. 2011;37(2):244–54.
  58. Lazarus S.C., Chinchilli V.M., Rollings N.J., Boushey H.A., Cherniack R., Craig T.J., Deykin A., DiMango E., Fish J.E., Ford J.G., Israel E., Kiley J., Kraft M., Lemanske R.F. Jr, Leone F.T., Martin R.J., Pesola G.R., Peters S.P., Sorkness C.A., Szefler S.J., Wechsler M.E., Fahy J.V.; National Heart Lung and Blood Institute’s Asthma Clinical Research Network. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am. J. Respir. Crit. Care Med. 2007;175:783–90.
  59. Chaudhuri R., Livingston E., McMahon A.D., Lafferty J., Fraser I., Spears M., McSharry C.P., Thomson N.C. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am. J. Respir. Crit. Care Med. 2006;174:127–33.
  60. Berry M., Morgan A., Shaw D.E., Parker D., Green R., Brightling C., Bradding P., Wardlaw A.J, Pavord I.D. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax. 2007;62:1043–49.
  61. Pavord I.D., Brightling C.E., Woltmann G., et al. Subclinical phenotypes of asthma. Curr. Opin. Allergy Clin. Immunol. 2010;10:54–9.
  62. Iwamoto H., Yokoyama A., Shiota N., Shoda H., Haruta Y., Hattori N., Kohno N. Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur. Respir. J. 2008;31:1379–82.
  63. Peters S.P., Bleecker E.R., Kunselman S.J., Icitovic N., Moore W.C., Pascual R., Ameredes B.T., Boushey H.A., Calhoun W.J., Castro M., Cherniack R.M., Craig T., Denlinger L.C., Engle L.L., Dimango E.A., Israel E., Kraft M., Lazarus S.C., Lemanske R.F. Jr, Lugogo N., Martin R.J., Meyers D.A., Ramsdell J., Sorkness C.A., Sutherland E.R., Wasserman S.I., Walter M.J., Wechsler M.E., Chinchilli V.M., Szefler S.J.; National Heart, Lung, and Blood Institute’s Asthma Clinical Research Network.Predictors of response to tiotropium versus salmeterol in asthmatic adults. J. Allergy Clin. Immunol. 2013;132(5):1068–74.
  64. Reihsaus E., Innis M., MacIntyre N., Liggett S.B. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am. J. Respir. Cell Mol. Biol. 1993;8(3):334–39.
  65. Umeda N., Yoshikawa T., Kanazawa H., Hirata K., Fujimoto S. Association of beta2-adrenoreceptor genotypes with bronchodilatory effect of tiotropium in COPD. Respirology. 2008;13(3):346–52.
  66. Bateman E.D., Kornmann O., Schmidt P., Pivovarova A., Engel M., Fabbri L.M. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J. Allergy Clin. Immunol. 2011;128(2):22–315.
  67. Ullah M.I., Newman G.B., Saunders K.B. Influence of age on response to ipratropium and salbutamol in asthma. Thorax. 1981;36:523–29.
  68. Connolly M.J., Ageing, late-onset asthma and the beta-adrenoceptor. Pharmacol. Ther. 1993;60:389–404.
  69. Partridge M.R., Saunders K.B. Site of action of ipratropium bromide and clinical and physiological determinants of response in patients with asthma. Thorax. 1981;36:530–33.
  70. Barua P., O’Mahony M.S. Overcoming gaps in the management of asthma in older patients: new insights. Drugs Aging. 2005;22(12):1029–59.
  71. Quizon A., Colin A.A., Pelosi U., Rossi G.A. Treatment of disorders characterized by reversible airway obstruction in childhood: are anti-cholinergic agents the answer? Curr. Pharm. Des. 2012;18(21):3061–85.
  72. Kelly H.W., Sternberg A.L., Lescher R., et al. Effect of inhaled glucocorticoids in childhood on adult height. N. Engl. J. Med. 2012;367:904–12.
  73. Robinson J.D., Angelini B.L., Krahnke J.S., Skoner D.P. Inhaled steroids and the risk of adrenal suppression in children. Expert Opin. Drug Saf. 2002;1:237–44.
  74. Callero-Viera A., Infante S., Fuentes-Aparicio V., Zapatero L., Alonso-Lebrero E. Neuropsychiatric reactions to montelukast. J Investig Allergol. Clin. Immunol. 2012;22:452–53.
  75. Chowdhury B.A., Dal Pan G., The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N. Engl. J. Med. 2010;362:1169–71.
  76. Xia Y., Kelton C.M., Xue L., Guo J.J., Bian B., Wigle P.R. Safety of long-acting beta agonists and inhaled corticosteroids in children and adolescents with asthma. Ther. Adv. Drug Saf. 2013;4(6):254–63.
  77. Food and Drug Administration (2010) FDA drug safety communication: New safety requirement for long-acting inhaled asthma medications called long-acting beta-agonists (LABAs). Available at: http://www,fda,gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200776,htm
  78. Cook A.L., Kinane T.B., Nelson B.A. Tiotropium Use in Pediatric Patients With Asthma or Chronic Cough: A Case Series. Clin. Pediatr. (Phila), 2014 Feb 23
  79. Teixeira M.F., Rodrigues J.C., Leone C., Adde F.V. Acute bronchodilator responsiveness to tiotropium in postinfectious bronchiolitis obliterans in children. Chest. 2013;144:974–80.
  80. Bradley J.M., Koker P., Deng Q., Moroni-Zentgraf P., Ratjen F., Geller D.E., Elborn J.S.; Tiotropium Cystic Fibrosis Study Group.Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PLoS One. 2014;9(9):e106195.
  81. Yoshida M., Nakano T., Fukuyama S., Matsumoto T., Eguchi M., Moriwaki A., Taka-ta S., Machida K., Kanaya A., Matsumoto K., Nakanishi Y., Inoue H. Effects of tiotropium on lung function in severe asthmatics with or without emphysematous changes. Pulm. Pharmacol. Ther. 2013;26(2):159–66.


Об авторах / Для корреспонденции


Е.А. Ушкалова – д.м.н., проф. кафедры общей и клинической фармакологии рудн; e-mail: eushk@yandex.ru


Похожие статьи


Бионика Медиа